BPC-157

A gastric pentadecapeptide studied mainly in animals for gut, tendon, and muscle injury models. Rodent results are often positive; quality human RCTs are essentially absent. It is not an FDA-approved medicine. US compounding policy remains restrictive after nomination withdrawal from Category 2 interim policy and FDA’s proposal against 503A Bulks List inclusion at the July 2026 PCAC.

A 15-residue fragment derived from a gastric protein. Proposed actions include angiogenic signaling (VEGFR2), nitric-oxide modulation, and effects on growth-factor pathways. Human target engagement is not established.

Dozens of animal studies report faster tendon and ligament healing and GI mucosal protection, including the 2019 preclinical soft-tissue review (PMID 30915550). Human evidence is anecdotal plus a few poorly controlled or unpublished reports. That gap is the story: mechanism hypotheses outrun clinical proof. PCAC discussion is regulatory process, not a new human evidence base.

Not FDA-approved. Nominations that previously placed BPC-157 under Category 2 of FDA’s compounding interim policy have been withdrawn; FDA’s Category 2 page now lists BPC-157 among bulk drug substances nominated but withdrawn, noting immunogenicity risk for some routes, peptide-related impurities, API characterization limits, and little safety information for proposed routes. At the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting, FDA considered BPC-157 (free base) and BPC-157 acetate for the 503A Bulks List for an ulcerative colitis–related nomination; FDA staff proposed that neither form be included. A PCAC discussion or vote is not a 503A listing and is not an approval. Research-chemical sales are not pharmacy drugs or approved medicines. Insurance does not pay for a research compound.

Not an FDA-approved drug. In 2023 FDA placed BPC-157 in Category 2 (significant compounding safety concerns). Nominators later withdrew that Category 2 placement; in July 2026 FDA's Pharmacy Compounding Advisory Committee narrowly recommended adding BPC-157 to the 503A bulks list for ulcerative colitis. A PCAC vote is not a listing, not an approval, and not a pharmacy green light. Until FDA actually places it on the bulks list, compounding is not a generally authorized US pathway. Research-chemical vendors remain the unofficial channel.

Same four pathways as the Sourcing guide.

No. Insurers do not pay for unapproved research peptides. A clinic cash protocol is not a covered benefit.

One of the most widely sold 'healing peptides' online, usually as a lyophilized vial labeled not for human use. Independent testing in adjacent research-chemical markets has found wrong identity, under-dosing, and contamination. There is no lot-level regulator behind those vials.

Strand does not list vendors. See the grey market.

There is no US prescribing label. Long-term human safety is unknown. Theoretical concerns include unregulated angiogenesis in occult malignancy. Product identity and sterility in research vials are not guaranteed. Do not treat animal milligram-per-kilogram figures as a human protocol.

• No adequate human RCTs; animal milligram-per-kilogram figures are not a human protocol.
• Theoretical angiogenesis concern in occult malignancy.
• Immunogenicity and characterization problems were why FDA staff opposed compounding.
• Sterility failure of a multi-use vial is an infection pathway.
• A PCAC recommendation is not permission to inject a research chemical.

• Preclinical tendon review · 2019 · Cell Tissue Res

  Gwyer, Wragg, Wilson. Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019. PMID 30915550.

• FDA Category 2 / withdrawn nominations

  BPC-157 appears under bulk drug substances nominated but withdrawn, with immunogenicity, impurity, characterization, and limited safety-information notes.

• PCAC July 23–24 2026 calendar

  Agenda lists BPC-157 (free base) and BPC-157 acetate for ulcerative colitis toward the 503A Bulks List. Committee discussion is not a listing.

• FDA PCAC slide deck

  Nominations withdrawn; FDA evaluating at its discretion. FDA proposes BPC-157 (free base) and BPC-157 acetate NOT be included on the 503A Bulks List.

• FDA BPC-157 PCAC briefing

  BPC-157-related bulk drug substances briefing for the July 2026 PCAC; notes withdrawn nominations and FDA evaluation at its discretion for 503A Bulks List consideration.